- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00004879
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
An Open Label, Multiple Dose, Dose-Rising Clinical Trial of the Safety of ABX-EGF in Patients With Renal, Prostate, Pancreatic, Non-Small-Cell Lung, Colorectal, or Esophageal Cancer
RATIONALE: Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody ABX-EGF in treating patients who have either renal (kidney), prostate, pancreatic, non-small cell lung, colon, rectal, esophageal, or gastroesophageal junction cancer.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
- Determine the safety of monoclonal antibody ABX-EGF in patients with renal, prostate, pancreatic, non-small cell lung, colorectal, esophageal, or gastroesophageal junction cancer.
- Determine the pharmacokinetics and the dose-response relationship of this drug in this patient population.
- Evaluate the clinical effect of this drug in this patient population.
OUTLINE: This is an open-label, dose-escalation, multicenter study.
Patients receive monoclonal antibody ABX-EGF IV over 1 hour once weekly on weeks 0-3* (enrollment for the weekly dosing schedule completed as of 4/21/03 [with the exception of patients undergoing full pharmacokinetic analyses, described below]) OR once every 2 weeks on weeks 0, 2, 4, and 6* OR once every 3 weeks on weeks 0, 3, 6, and 9*. Patients undergoing full pharmacokinetic analyses receive a loading dose on week 0 and the subsequent 3 doses on weeks 3-5.
NOTE: *All patients receive a total of 4 doses.
Cohorts of 2-8 patients receive escalating doses of monoclonal antibody ABX-EGF until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 or 3 patients experience dose-limiting toxicity.
Patients are followed every 2 weeks for 5 weeks.
PROJECTED ACCRUAL: A total of 76 patients will be accrued for this study within approximately 14 months.
Tipo de estudio
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90095-1738
- Jonsson Comprehensive Cancer Center, UCLA
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19111
- Fox Chase Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Histologically confirmed diagnosis of 1 of the following:
Renal cell cancer (RCC)
- Prior nephrectomy required
Prostate cancer
- Failed prior primary therapy (e.g., surgery, radiotherapy, or chemotherapy)
- Failed prior hormonal therapy (e.g., antiandrogen, luteinizing hormone-releasing hormone inhibitor, or orchiectomy)
Pancreatic cancer
- Failed at least 1 prior standard therapy regimen for unresectable metastatic disease
Non-small cell lung cancer
- Failed at least 1 prior standard therapy regimen for unresectable metastatic disease
Colorectal cancer
- Received 1 or more prior chemotherapy regimen(s) for advanced metastatic disease
Esophageal cancer
- Failed prior primary therapy (e.g., surgery, radiotherapy, or chemotherapy)
- Gastroesophageal junction cancer
- Evaluable disease
Epidermal growth factor receptor overexpression
- Tumor tissue must yield the sum of 1+, 2+, or 3+ staining in at least 10% of evaluated tumor cells
- No uncontrolled brain metastases
- No evidence of disease progression or regression after a 30-day washout period
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Karnofsky 70-100% OR
- ECOG 0-1
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count greater than 1,000/mm^3
- Platelet count greater than 100,000/mm^3
Hepatic:
- AST/ALT no greater than 2 times upper limit of normal (ULN) (3 times ULN for liver metastases)
- Alkaline phosphatase no greater than 2 times ULN (3 times ULN for liver metastases)
Renal:
- Creatinine less than 2.2 mg/dL
- NCI renal toxicity no greater than grade 2
- No hypercalcemia (antihypercalcemic therapy allowed)
Cardiovascular:
- Ejection fraction at least 45% by MUGA
- No abnormal ECG or MUGA
- No myocardial infarction within the past year
Pulmonary:
- No abnormal chest x-ray
- FEV_1 greater than 50% of predicted
Other:
- No known allergy to ingredients of study drug
- No known allergy to Staphylococcus aureus Protein A
- HIV negative
- No chronic medical or psychiatric condition that would preclude study compliance
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 2 months after study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 30 days since prior biologic therapy (e.g., antibodies, cytokines, or co-stimulatory pathway inhibitors)
- No other concurrent biologic therapy
Chemotherapy:
- See Disease Characteristics
- At least 6 weeks since prior chemotherapy and recovered
- No prior chemotherapy for RCC
- No prior anthracyclines
- No concurrent chemotherapy
Endocrine therapy:
- See Disease Characteristics
- Concurrent steroids allowed
- Concurrent hormonal therapy allowed
Radiotherapy:
- See Disease Characteristics
- No prior mediastinal radiotherapy
- No concurrent radiotherapy
Surgery:
- See Disease Characteristics
- Recovered from any recent prior surgery
Other:
- At least 30 days since prior investigational drug or device
- At least 30 days since prior systemic therapy
- No other concurrent investigational drugs
- No other concurrent systemic agents or cancer therapy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Enmascaramiento: Ninguno (etiqueta abierta)
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias Urológicas
- Neoplasias urogenitales
- Neoplasias por sitio
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades del sistema endocrino
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Neoplasias de glándulas endocrinas
- Neoplasias Genitales Masculinas
- Enfermedades prostáticas
- Neoplasias de Cabeza y Cuello
- Enfermedades esofágicas
- Enfermedades pancreáticas
- Neoplasias Renales
- Neoplasias prostáticas
- Neoplasias pancreáticas
- Neoplasias Esofágicas
- Agentes antineoplásicos
- Agentes antineoplásicos inmunológicos
- Panitumumab
Otros números de identificación del estudio
- CDR0000067539
- UCLA-9906078
- ABX-EG-9901
- UCLA-9906078-04B
- NCI-G00-1673
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cancer de RIÑON
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento
Ensayos clínicos sobre panitumumab
-
University of Alabama at BirminghamReclutamiento
-
Radboud University Medical CenterTerminadoAdenocarcinoma de esófago irresecable de células escamosasPaíses Bajos
-
WiSP Wissenschaftlicher Service Pharma GmbHGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHTerminadoCáncer de vejiga urinariaAlemania
-
Spanish Cooperative Group for the Treatment of...AmgenTerminado
-
TakedaTerminado
-
Cliniques universitaires Saint-Luc- Université...Terminado
-
Gruppo Oncologico del Nord-OvestTerminadoCáncer colorrectal metastásicoItalia
-
University of UtahTerminadoCáncer colorrectal de tipo salvaje KRAS y NRASEstados Unidos
-
Hellenic Cooperative Oncology GroupTerminado
-
Gruppo Oncologico del Nord-OvestBayer; AmgenReclutamientoCáncer colonrectalItalia